SI
RYTM icon

Sofinnova Investments’s Rhythm Pharmaceuticals RYTM Stock Holding History

Sofinnova Investments’s Portfolio RYTM Stock Details RYTM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-225,000
Closed -$14.2M – 72
2025
Q2 		$14.2M Buy
+225,000
New +$13.8M 0.87% 34

Other funds holding RYTM

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Sofinnova Investments's RYTM Position: Q2 2026 in Review

Sofinnova Investments reduced its Rhythm Pharmaceuticals (RYTM) stake by 9.3% in Q2 2026, selling an estimated $3.8M and leaving 408,027 shares worth $45.3M. The position accounts for 2.34% of the portfolio, ranked #12.

Sofinnova Investments first reported a position in RYTM in Q2 2018 and has held it in 11 quarters since. 304 funds tracked by Wall St. Rank hold RYTM as of Q2 2026.

  • Sofinnova Investments held 408,027 shares of Rhythm Pharmaceuticals worth $45.3M as of Q2 2026.
  • Sofinnova Investments sold 42,069 Rhythm Pharmaceuticals shares in Q2 2026, an estimated $3.8M.
  • Rhythm Pharmaceuticals made up 2.34% of Sofinnova Investments's portfolio in Q2 2026, its #12 holding.
  • Sofinnova Investments first reported a position in Rhythm Pharmaceuticals in Q2 2018 and has held it in 11 quarters since.
  • 304 funds tracked by Wall St. Rank held Rhythm Pharmaceuticals as of Q2 2026.

Based on Sofinnova Investments's 13F filing for Q2 2026, filed 14 Aug 2026.